Clinical trials: Pneumococcal Vaccines
- Condition Pneumococcal Vaccines
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Pneumococcal Disease
A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
The purpose of this study is to learn about the safety of 20-valent Pneumococcal Conjugate Vaccine (PREVENAR 20) under actual clinical practice in Japan.
- Trial name
- NCT06622109
- Testing
- 20-valent Pneumococcal Conjugate Vaccine
- Where
- Japan
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Pneumococcal Infectious Disease
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday).
- Trial name
- NCT06617715
- Testing
- Sinovac PCV13, Prevnar®
- Where
- China
- Volunteers
- 3,080 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Pneumococcal Vaccines, Pneumococcal Infections
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine
The goal of this clinical trial is to evaluate the immunogenicity and safety of Minhai's 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-DT/TT) as compared to Pfizer's 13-valent Pneumococcal Conjugate Vaccine…
- Trial name
- NCT06608199
- Testing
- pneumococcal disease prevention
- Where
- 3 sites in Indonesia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Infections, Streptococcal
Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment
The aim of the current study is to determine whether ibuprofen, given as immediate or delayed prophylactic antipyretic treatment in a standardized manner, significantly impacts the immune response in children receiving primary…
- Trial name
- NCT01235949
- Testing
- GSK1024850A (SynflorixTM), Infanrix hexa, Infanrix-IPV/Hib
- Where
- 23 sites in Romania
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections, Pneumococcal Vaccines
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V114 in healthy infants. The primary hypotheses are that: 1) V114 is non-inferior to Prevnar 13™ for the 13 shared serotypes between V114…
- Trial name
- PNEU-PED (NCT03893448)
- Testing
- V114, Prevnar 13™, RotaTeq™
- Where
- 81 sites in United States, Puerto Rico and 2 more
- Volunteers
- 1,720 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Vaccines, Pneumococcal
Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal vaccine (13vPnC) compare to the 7-valent pneumococcal vaccine (7vPnC) and to compare the immune response to…
- Trial name
- NCT00373958
- Testing
- 13 valent pneumococcal conjugate vaccine, 7vPnc pneumococcal conjugate vaccine
- Where
- 37 sites in United States
- Volunteers
- 666 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Immunization, Safety
A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market
The purpose of this study is to understand the safety of Prevenar 20 (Pneumococcal 20-valent conjugate vaccine) once it is out in the Korean market.
- Trial name
- NCT06760208
- Testing
- Pneumococcal 20-valent conjugate vaccine
- Where
- South Korea
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Prevenar13 Post Market Surveillance
It is an observational multi-center study to assess the safety profile of Prevenar13 used among Korean children in the routine clinical setting following a licensure and introduction of the vaccine.
- Trial name
- NCT01509105
- Testing
- 13-valent pneumococcal vaccine
- Where
- 18 sites in South Korea
- Volunteers
- 649 people
- Sponsor
- Pfizer
Streptococcus Pneumoniae Infection
Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
This clinical trial consists of Phase I and Phase II. The objective is to evaluate the safety and immunogenicity of the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) in individuals aged 2 months…
- Trial name
- NCT07600983
- Testing
- 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M), PCV24 vaccine (dose H), PCV24 vaccine (dose M)
- Where
- 2 sites in China
- Volunteers
- 854 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Infections, Streptococcal
Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A
The aim of the study is to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals' pneumococcal conjugate vaccine GSK1024850A.
- Trial name
- NCT01175083
- Testing
- GSK1024850A (Synflorix), Tritanrix-HepB/Hib, Polio Sabin
- Where
- Burkina Faso
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Meningitis, Measles
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
This is a Phase III, modified single-blind, randomized, parallel-group, multicenter, comparative trial in the United States designed to evaluate the immunogenicity and safety of two doses of Menactra vaccine administered alone…
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella
- Trial name
- NCT00384397
- Testing
- Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Where
- 39 sites in United States
- Volunteers
- 1,128 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumococcal Infections, Pneumococcal Conjugate Vaccine
A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children
The purpose of this study is to assess the safety and immunogenicity of 13-valent Pneumococcal conjugate vaccine in Chinese infant and young children.
- Trial name
- NCT03574389
- Testing
- 13vPnC, Hib
- Where
- 2 sites in China
- Volunteers
- 936 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations…
- Trial name
- NCT00452790
- Testing
- 13-valent Pneumococcal Conjugate Vaccine, 7 valent pneumococcal conjugate vaccine
- Where
- 12 sites in India
- Volunteers
- 708 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Infections, Streptococcal
Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™
The purpose of this study is to assess the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following primary vaccination of…
- Trial name
- NCT00678301
- Testing
- GSK Biologicals' Synflorix™, GSK Biologicals' Polio Sabin™, GSK Biologicals' Zilbrix™ Hib
- Where
- 2 sites in Mali, Nigeria
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease
A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers
In 2005, Wyeth conducted study 0887X-101518 (NCT00488826) in which Chinese infants received either Prevenar alone (Group 1), Prevenar given with a Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccine (Group 2) or DTaP alone…
- Trial name
- NCT01298544
- Testing
- Blood draw
- Where
- 10 sites in China
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vaccines
Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India
A Phase 4 Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India
- Trial name
- NCT03548337
- Testing
- 13vPnC
- Where
- 7 sites in India
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatitis B, Polio
Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants
The purpose of the study is to provide immunogenicity and safety data of the investigational hexavalent vaccine when it is given concomitantly (the same day at separate injection sites) with Prevnar, according to the 2-4-6 month…
- Conditions
- Hepatitis B, Polio, Diphtheria, Pertussis
- Trial name
- NCT00401531
- Testing
- DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines, DTaP-HB-IPV and Pneumococcal polysaccharide vaccines
- Where
- 2 sites in Thailand
- Volunteers
- 412 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Vaccines, Pneumococcal
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations…
- Trial name
- NCT00366899
- Testing
- 13-valent pneumococcal conjugate vaccine, 7 valent pneumococcal conjugate vaccine
- Where
- 13 sites in Italy
- Volunteers
- 605 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Immunisation Against Streptococcus Pneumoniae
Post-marketing Safety Study of GlaxoSmithKline (GSK) Biologicals' Synflorix™ Vaccine, in Healthy Infants and Children in Sri Lanka
This PMS study aims to collect safety and reactogenicity data of Synflorix™ in healthy infants and children of the local population as per the licensing requirement of the Sri Lankan regulatory authority.
- Trial name
- NCT01803425
- Testing
- Synflorix™ data collection
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years
A Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years.
- Trial name
- NCT07300644
- Testing
- Sinovac PCV24, Prevnar®
- Where
- 3 sites in China
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.